✦ LIBER ✦

A trial of buspirone for the control of disruptive behaviors in community-dwelling patients with dementia

✍ Scribed by Mark A. Levy; Louis D. Burgio; Robert Sweet; Paula Bonino; Janine Janosky; James Perel

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 628 KB
Volume: 9
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.930091012

No coin nor oath required. For personal study only.

✦ Synopsis

We report the results of a pilot study examining the dose-response of buspirone for the treatment of agitated and disruptive behaviors in dementia patients. Patients were identified by physician referral, chart review and caregiver response to newspaper advertisements. All subjects met NINCDS-ADRDA criteria for probable Alzheimer's disease. Twenty subjects were entered into the study, 12 completed the protocol. After a washout period, all subjects received 1 week of placebo followed by approximately 2 weeks each of buspirone 15 mg, 30 mg, 45 mg and 60 mg daily. The primary outcome measure was the total score on Reisberg's Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), which was administered at baseline, the end of the placebo phase and at the end of each dosage interval. Significant improvement in the mean score was seen at a daily dosage of 30 mg (p < 0.05 vs placebo). Significant improvement was also seen on the delusion, aggression and anxiety subscales of the BEHAVE-AD. Few side-effects were noted. These data suggest that the optimal starting dosage of buspirone for the treatment of behavioral pathology in dementia patients is 30 mg daily. Individual patients may have their best response at dosages ranging from 15 to 60 mg daily. Confirmation of these findings requires a double-blind, placebo-controlled clinical trail.

KEY worm-Dementia, buspirone, agitation.

Disruptive, agitated and aggressive behaviors are common in patients with dementia (Teri etal., 1988;Rubin et a/., 1988;Reisberg et al., 1987). These behaviors are a major source of caregiver stress and frequently lead to nursing home placement (Ferris et al., 1985). Despite the growing acceptance and utilization of non-pharmacologic interventions and increasing institutional regulations limiting the use of pharmacotherapy, psychotropic drug ther-

📜 SIMILAR VOLUMES

The cost of behavioral and psychological

The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients

✍ Michal Schnaider Beeri; Perla Werner; Michael Davidson; Shlomo Noy 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract ## Introduction Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent in Alzheimer's disease (AD) patients. They are a source of distress for the caregivers and one of the main reasons for nursing home placement, which is the major component of the cost of Alzhe

A randomized controlled trial to examine

A randomized controlled trial to examine the effectiveness of case management model for community dwelling older persons with mild dementia in Hong Kong

✍ Linda C. W. Lam; Jenny S. W. Lee; Jenny C. C. Chung; Anna Lau; Jean Woo; Timothy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

## Abstract ## Objective To evaluate a case management (CM) model for people with mild dementia, whereby resources within the family and in the community were mobilized and optimally used. ## Method Community dwelling psychiatric and geriatrics outpatients with mild dementia were randomized to r

Sodium valproate in the treatment of agg

Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial

✍ Rob C. Sival; P. M. Judith Haffmans; Paul A. F. Jansen; Sijmen A. Duursma; Piet 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 3 views

## Objectives: The efficacy and tolerability of sodium valproate 2 x 240 mg compared to placebo were investigated in aggressive behavior in dementia. ## Design: A randomized, placebo controlled, double-blind cross-over design. the trial included a baseline period (one week); a placebo period (thr

A randomized, controlled trial of bright

A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care

✍ Constantine G. Lyketsos; Lori Lindell Veiel; Alva Baker; Cynthia Steele 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

Background. Agitated behaviors are common in dementia patients residing in chronic care settings. Their occurrence may be associated with lack of adequate exposure to sunlight and with circadian rhythm disturbances. Objective. Prior research has suggested that bright light therapy (BLT) may reduce

A randomized controlled trial of a behav

A randomized controlled trial of a behavior advisory service for hospitalized older patients with confusion

✍ Julie E. Mador; Lynne Giles; Craig Whitehead; Maria Crotty 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract ## Objective To determine whether individualized advice on non‐pharmacological strategies for hospitalized older patients with confusion and behavioral problems can improve levels of agitation and reduce the use of psychotropic medication. ## Method Pragmatic randomized controlled tr

A randomized, controlled, clinical trial

A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care

✍ Antonios M. Politis; Stephen Vozzella; Lawrence S. Mayer; Chiadi U. Onyike; Alva 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## Abstract ## Background Apathy is a common symptom in patients with dementia and has adverse consequences for patients and caregivers. Most treatments for apathy, particularly non‐pharmacologic interventions, have not been evaluated in controlled trials. ## Objectives This study evaluated the